Company intelligence / Profile preview

Emiliem

San Antonio, Texas, United States

Ownership: Private
Development stage: Other

Overview

Emiliem is a clinical-stage biotechnology company based in San Antonio, Texas, focused on developing novel small molecule inhibitors for oncology. The company's research centers on targeting critical signaling pathways that drive tumor growth and survival, particularly the PI3K/mTOR and DNA-PK pathways. Its lead clinical candidate, EM-058, is a dual PI3K/mTOR inhibitor designed to treat various solid tumors and hematological malignancies. Emiliem aims to provide more effective treatment options by addressing the limitations of current kinase inhibitors through improved potency and selectivity. The company leverages its expertise in medicinal chemistry to advance a pipeline of targeted therapies for life-threatening diseases.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Emiliem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emiliem.

Explore the full profile